Nanoparticles come in many shapes and sizes, each specifically designed to play a precise role in cancer treatment. And now, researchers from UC Davis have created nanotechnology with the ability to perform multiple tasks and the ultimate goal of destroying tumors.
Polymer nanomaterials are crucial for many types of drug delivery applications, offering the flexibility and durability needed to engineer specific shapes and sizes for particular delivery solutions. Now, at Carnegie Mellon, researchers have developed a new technique for creating self-assembling fibers for this purpose, taking a cue from the natural fibers in living cells.
Like the tiny organelles used to propel some bacteria, artificial cilia developed by German engineers could someday help deliver drugs.
Researchers have found a way to use nanoparticles to deliver drugs that can "wake up" the immune system and fortify its natural response to harmful cancer cells in the body.
Researchers are hoping to get into the clinic in the next three to 5 years with a self-assembling nanoparticle that targets tumors. The idea behind the technology is to make cancer cells more identifiable when using magnetic resonance imaging screening.
Patients with pancreatic cancer whose disease still persists after regular treatments may benefit from a new cancer drug nanoliposome formulation, according to a presentation at the European Society for Molecular Oncology's 16th World Congress on Gastrointestinal Cancer.
The FDA's new draft industry guidance on the use of nanomaterials in animal feed could ramp up production in drug delivery products for livestock, as companies scramble to find new ways of fattening them up--and faster.
Researchers in Boston have developed new drug-delivering nanoparticles that could target and kill bone cancer cells by homing in on calcium. Besides showing in mouse models to slow myeloma growth and prolonging survival, the treatment also enhanced bone strength and volume.
The FDA on June 24 issued three final guidances and a draft guidance for industry to clarify the use of nanotechnology in FDA-regulated products, a decision that will affect the drug delivery arena as it becomes more dependent on nano-engineerin g.
Researchers at UC Santa Barbara have concocted a new type of silver nanoparticle designed to deliver cancer drugs that can also dissolve and become inactive if it doesn't reach the tumor. The innovation solves some safety issues associated with nanotechnology and reduces side effects from the cancer drugs themselves, the scientists say.